Abstract

Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133
R I Fisher ... P A Ganz
Journal of Clinical Oncology | VOL. 22
R I Fisher, et. al.R I Fisher ... P A Ganz
15 Jul 2004
Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin's Disease.
Hildtrud Nisters-Backes ... Andreas Josting
Blood | VOL. 106
Hildtrud Nisters-Backes, et. al.Hildtrud Nisters-Backes ... Andreas Josting
16 Nov 2005
Reduction of treatment for early stage Hodgkin's disease
Peter Mauch
International Journal of Radiation Oncology, Biology, Physics | VOL. 22
Peter MauchPeter Mauch
01 Jan 1992
Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients
E Zucci ... F Cavalli
Leukemia & Lymphoma | VOL. 44
E Zucci, et. al.E Zucci ... F Cavalli
01 Jan 2003
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers